Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 10Recurrence 2Neoplasms 2Neoplasm Metastasis 2Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma 1Oligodendroglioma 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Ependymoma 1Breast Neoplasms 1Breast Carcinoma In Situ 1Brain Neoplasms 1Astrocytoma 1Adult Solid Neoplasm 1

Interventions

temsirolimus 2Sirolimus 2Gemcitabine 2ARQ 197 2veliparib 1sargramostim 1pegfilgrastim 1ixabepilone 1cixutumumab 1belinostat 1Vorinostat 1Topotecan 1Tolbutamide 1Taxes 1Sunitinib 1Rifampin 1Paclitaxel 1Omeprazole 1Midazolam 1Ketoconazole 1Isotretinoin 1Irinotecan 1Introns 1Interferon alpha-2 1Hydroxychloroquine 1Erlotinib Hydrochloride 1Epothilones 1Dextromethorphan 1Colony-Stimulating Factors 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Adult Solid Neoplasm × Introns × Clear all
NCT00217373 2015-04-20

Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)

National Cancer Institute (NCI)

Phase 1 Completed
33 enrolled

Adult Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡